Loading
Pharmacology and Obesity Treatment / Diabetes Treatment and Management / Regulation of Appetite and Obesity · Journal article
Frontiers in Endocrinology · September 7, 2026
A consensus or society position rather than new primary data.
This is a narrative review that surveys the landscape of obesity management, from lifestyle modification through approved pharmacotherapies (particularly GLP-1 and GIP/GLP-1 agonists) to emerging agents under development. The text reports that GLP-1 and dual GIP/GLP-1 receptor agonists have demonstrated unprecedented efficacy in achieving clinically meaningful and sustained weight loss, but provides no quantified effect sizes, comparisons, or new trial results; it is therefore an integrative overview intended to inform clinical and research understanding rather than evidence-based guidance for specific decisions.
Narrative review.
GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists have demonstrated unprecedented efficacy in achieving clinically meaningful and sustained weight loss. Novel agents including triple agonists, oral peptide formulations, and combination therapies are currently undergoing clinical evaluation.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
A narrative review synthesising current understanding of obesity management across non-pharmacological, herbal, approved pharmacological and emerging therapeutic strategies, without presenting new primary data or systematic evidence synthesis.
As stated by the source record.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Obesity is a long-term, complex disorder characterised by excessive adiposity that increases the risk of metabolic and cardiovascular diseases. Obesity is a significant health problem, with its prevalence increasing steadily over the last several decades. This rising trend has contributed substantially to the burden of metabolic, cardiovascular and other chronic diseases. Lifestyle modification remains the primary approach to obesity treatment; long-term weight reduction is difficult to achieve and sustain due to complex neurohormonal mechanisms that regulate appetite and energy homeostasis. Consequently, pharmacotherapy has become an essential component of comprehensive obesity management in appropriately selected patients. Recent advances in obesity pharmacology have revolutionised treatment strategies, particularly with the introduction of incretin-based therapies such as glucagon-like peptide-1 (GLP-1) receptor agonists and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists, which have demonstrated unprecedented efficacy in achieving clinically meaningful and sustained weight loss. Furthermore, several novel agents, including triple agonists, oral peptide formulations, and combination therapies, are currently undergoing clinical evaluation and are expected to further transform obesity treatment. This review provides the current understanding of obesity pharmacotherapy, discusses approved anti-obesity medications, highlights emerging therapeutic agents and drugs under clinical development, and explores future perspectives in obesity management. Additionally, the review addresses current challenges, safety concerns, and public health strategies required to combat the growing obesity epidemic.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.